243 related articles for article (PubMed ID: 28745110)
1. [Not Available].
Bächli E; Gundelfinger M
Praxis (Bern 1994); 2017 Jul; 106(15):807-813. PubMed ID: 28745110
[No Abstract] [Full Text] [Related]
2. Straightforward identification of masked polycythemia vera based on proposed revision of World Health Organization diagnostic criteria for BCR-ABL1-negative myeloproliferative neoplasms.
Chu D; Cho YU; Jang S; Seo EJ; Park CJ
Ann Lab Med; 2015 Nov; 35(6):651-3. PubMed ID: 26354357
[No Abstract] [Full Text] [Related]
3. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
4. Aquagenic pruritus and the JAK2 V617F mutation.
Langabeer SE
Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
[No Abstract] [Full Text] [Related]
5. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
6. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation.
Suknuntha K; Geyer JT; Patel KP; Weinberg OK; Rogers HJ; Lake JI; Lauridsen L; Patel JL; Kluk MJ; Arber DA; Hsi ED; Bagg A; Bueso-Ramos C; Orazi A
Leuk Res; 2023 Apr; 127():107033. PubMed ID: 36774789
[TBL] [Abstract][Full Text] [Related]
7. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
[No Abstract] [Full Text] [Related]
8. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
9. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
Campr V
Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
[TBL] [Abstract][Full Text] [Related]
10. Erythrocytosis due to presumed polycythemia vera.
Patell R; Theil K; Lichtin A
Cleve Clin J Med; 2016 Sep; 83(9):648-53. PubMed ID: 27618352
[No Abstract] [Full Text] [Related]
11. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
[No Abstract] [Full Text] [Related]
12. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
[No Abstract] [Full Text] [Related]
13. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
Tondeur S; Paul F; Riou J; Mansier O; Ranta D; Le Clech L; Lippert E; Tavitian S; Chaoui D; Mercier M; De Renzis B; Cottin L; Cassinat B; Chrétien JM; Ianotto JC; Allangba O; Marzac C; Voillat L; Boyer F; Orvain C; Hunault-Berger M; Girodon F; Kiladjian JJ; Ugo V; Luque Paz D
Leukemia; 2021 Mar; 35(3):871-875. PubMed ID: 32694617
[No Abstract] [Full Text] [Related]
15. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
16. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
17. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
18. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.
James C; Delhommeau F; Marzac C; Teyssandier I; Couédic JP; Giraudier S; Roy L; Saulnier P; Lacroix L; Maury S; Tulliez M; Vainchenker W; Ugo V; Casadevall N
Leukemia; 2006 Feb; 20(2):350-3. PubMed ID: 16341032
[No Abstract] [Full Text] [Related]
19. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
20. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
